Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Cash & Current Investments (2020 - 2026)

Aura Biosciences filings provide 7 years of Cash & Current Investments readings, the most recent being $84.8 million for Q1 2026.

  • Quarterly Cash & Current Investments rose 121.82% to $84.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $84.8 million through Mar 2026, up 121.82% year-over-year, with the annual reading at $59.5 million for FY2025, 87.79% up from the prior year.
  • Cash & Current Investments hit $84.8 million in Q1 2026 for Aura Biosciences, up from $59.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $107.4 million in Q2 2025 and bottomed at $19000.0 in Q4 2023.
  • Average Cash & Current Investments over 5 years is $32.4 million, with a median of $30.1 million recorded in 2024.
  • Peak annual rise in Cash & Current Investments hit 305450.0% in 2022, while the deepest fall reached 99.99% in 2022.
  • Aura Biosciences' Cash & Current Investments stood at $20000.0 in 2022, then dropped by 5.0% to $19000.0 in 2023, then skyrocketed by 166705.26% to $31.7 million in 2024, then surged by 87.79% to $59.5 million in 2025, then surged by 42.47% to $84.8 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Cash & Current Investments are $84.8 million (Q1 2026), $59.5 million (Q4 2025), and $47.6 million (Q3 2025).